Specialties

Data analysis suggests the need to create CVD prediction models specifically focused on the risk factors that affect patients with type 2 diabetes. 

Patients with cardiac implantable electronic devices (CIEDs) who received an SGLT2i had a significantly lower incidence of atrial arrhythmia (AA) compared to placebo. 

DAPA-CKD trial results indicate a significant benefit for SGLT2 inhibitor dapagliflozin in reducing chronic kidney disease progression and mortality caused by kidney failure and cardiovascular disease, regardless of diabetes status. 

Hyperuricemia has been implicated in the development and progression of chronic kidney disease, and the effects of intensive albuminuria lowering may be beneficial. 

Trials tested the hypothesis that treating patients with intensive therapy to target normal glycated hemoglobin A1c levels would positively affect cardiovascular risk. 

Baseline hemoglobin A1C may be inversely proportional to the risk of statin-induced new-onset diabetes. 

Seventeen common biomarkers were differentially expressed in patients with Alzheimer’s Disease or type 2 diabetes when compared with healthy controls. 

According to research presented by Dr. George Bakris of the University of Chicago, treatment with finerenone resulted in a lower risk of the progression of chronic kidney disease and cardiovascular events. 

Insulin-dependent diabetes mellitus may be linked to male reproductive dysfunction. 

Patients who suffer from mild to extreme mental health stress are less likely to participate in self-care behavior for diabetes.